'. . . Once-daily tiotropium + olodaterol FDC [Fixed Dose Combination] is an investigational combination that includes the long-acting muscarinic antagonist (LAMA) tiotropium with olodaterol, a long-acting beta agonist (LABA), delivered via the propellant-free Respimat® inhaler, which generates a slow-moving mist.
The pivotal 52-week TONADO™ 1&2 studies included more than 5,500 patients with COPD. Results showed that lung function, as measured by trough forced expiratory volume in one second (FEV1), improved in patients receiving tiotropium + olodaterol FDC delivered via the Respimat® inhaler, and that St. George’s Respiratory Questionnaire (SGRQ) total score was affected favorably compared to those receiving olodaterol or tiotropium alone. . . .'
Trough FEV1responses at 24 weeks:
Olodaterol 5 μg 55 ml
Tiotropium 5 μg 80 ml
T+O 5/5 μg 140 ml